Mylan ( Mylan )

Mylan

Mylan's picture

Mylan is one of the world’s leading generics and specialty pharmaceutical companies, providing products to customers in approximately 150 countries and territories. The company maintains one of the industry’s broadest and highest quality product portfolios, which is regularly bolstered by an innovative and robust product pipeline. With a workforce of more than 18,000, Mylan has attained leading positions in key international markets through its wide array of dosage forms and delivery systems, significant manufacturing capacity, global commercial scale and a committed focus on quality and customer service.

Mylan press release, blog etc

02/01/2018 - 06:04 Mylan Expands Access to HIV/AIDS Medicines with Launch of First Generic Sustiva Tablets
01/29/2018 - 06:07 Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
01/29/2018 - 03:23 Mylan and Biocon Receive Positive CHMP Opinion for Semglee, Biosimilar Insulin Glargine
12/29/2017 - 10:26 Mylan Adds to U.S. Women's Healthcare Portfolio With FDA Approval of First Generic for Estrace Cream
12/28/2017 - 23:10 Biocon and Mylan's Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through their Partner Libbs
12/14/2017 - 05:50 Mylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All Claims Against Sanofi's Lantus Patents
12/11/2017 - 11:37 Teva Dismisses Litigation After Mylan Wins U.S. Court Ruling Related to Teva's Cold Filtration Patents for Copaxone 40 mg/mL
12/04/2017 - 05:43 Mylan and Aspen Announce Launch of Generic Busulfex Injection
12/01/2017 - 07:54 U.S. FDA Approves Mylan and Biocon's Ogivri, the First Biosimilar for Trastuzumab, for the Treatment of HER2-Positive Breast and Gastric Cancers
11/30/2017 - 11:57 European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon's Proposed Biosimilars Trastuzumab and Pegfilgrastim
11/13/2017 - 09:12 Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
11/10/2017 - 13:15 Mylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange (TASE)
11/09/2017 - 05:06 Mylan Launches Generic Clolar for Injection
11/01/2017 - 07:51 Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting
10/27/2017 - 14:39 Mylan's EpiPen4Schools Program Surpasses One Million Free Epinephrine Auto-Injector Donations to U.S. Schools
10/26/2017 - 06:51 Mylan Wins UK Court Ruling Related to Copaxone 40 mg/mL Patent
10/05/2017 - 11:39 Mylan, in Partnership with Synthon, Receives Marketing Authorization Approval in Europe for First Generic for Copaxone 40 mg/mL
10/04/2017 - 03:16 Mylan Provides Support for U.S. Disaster-Relief Efforts